Observed Signal · Sep 3, 2026 · Market Signal · Source: AbbVie · Impact: 4.5/5
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...
MARKET SIGNALS
Track AbbVie Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...
Intensity Therapeutics Presents INVINCIBLE-4 TNBC Data
Intensity Therapeutics announced that data from the first seven patients in Cohort A of the INVINCIBLE-4 study will be presented at the ESMO 2026 congress. The study evaluates INT230-6, an intratumoral therapy, in combination with neoadjuvant immunochemotherapy (NAIC) for early-stage triple-negative breast cancer (TNBC). Results showed a pathological complete response (pCR) in the breast and lymph nodes in 5 of 7 patients (71%). No invasive cancer cells in axillary lymph nodes were detected in 6 of 7 patients, despite 71% being initially node-positive. Tumor necrosis was observed in all patients after 1-2 injections. Adverse events were low grade, with dose-limiting skin reactions. The data suggest potential efficacy of INT230-6 in this setting.
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Johnson & Johnson announced new overall survival data and treatment experience improvements for RYBREVANT-based regimens in EGFR-mutated lung cancer at WCLC 2026. Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC will be featured in a Presidential Symposium. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO and prophylactic strategies.
WATCHLIST & BRIEFINGS
Receive future signals for AbbVie & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor AbbVie
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
